The Debiopharm Innovation Fund strategically invests in early-stage startups focused on digital health, AI, and data solutions to transform pharmaceutical R&D and cancer care. Their strategy targets companies developing innovative therapeutics, diagnostics, and smart data solutions across Next Gen Pharma R&D, Clinical Trial Tech, and Digital Medicine.
Their most common stage is series-a (50% of deals). Average disclosed round size is $11.5M (across 3 rounds with reported amounts).
Portfolio
4
Fund Size
$150M
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
Top Co-Investors
M Ventures1 shared
Omnes Capital1 shared
Philips Health Technology Ventures1 shared
HLM Venture Partners1 shared
LRVHealth1 shared
Taiwania1 shared
First Star Venture1 shared
Redalpine1 shared
Last updated: 10 April 2026